Arianna Barbetta1, Smita Sihag1, Tamar Nobel1, Meier Hsu2, Kay See Tan2, Manjit Bains1, David R Jones1, Daniela Molena3. 1. Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. 2. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. 3. Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: molenad@mskcc.org.
Abstract
OBJECTIVES: A pathologic complete response in patients with locally advanced esophageal cancer after chemoradiotherapy and surgery is associated with improved overall and disease-free survival. Nevertheless, approximately one third of patients with a pathologic complete response still have a recurrence. The aim of this study was to evaluate risk factors and patterns of recurrence in patients with locally advanced esophageal cancer who achieved a pathologic complete response after chemoradiotherapy and surgery. METHODS: We performed a retrospective review of a single-institution database of 233 patients with stage II and III esophageal cancer with a pathologic complete response after chemoradiotherapy and surgery between 1997 and 2017. A multivariable competing risk-regression model was used to identify predictors of recurrence. RESULTS: A total of 61 patients exhibited recurrence in this cohort, 43 with adenocarcinoma and 18 with squamous cell carcinoma. Five-year cumulative incidence of recurrence did not vary by histology. Univariable analysis revealed that poor tumor differentiation (hazard ratio, 2.28; P = .022) and advanced clinical stage (hazard ratio, 1.89; P = .042) are predictors of recurrence in the esophageal adenocarcinoma subgroup, whereas poor tumor differentiation remained the only independent predictor on multivariable analysis in the entire cohort (hazard ratio, 2.28; P = .009). Patients with esophageal adenocarcinoma had a higher incidence of distant recurrences, and patients with esophageal squamous cell carcinoma demonstrated a higher incidence of loco-regional recurrence (P = .039). CONCLUSIONS: Poor tumor differentiation is an independent risk factor for recurrence in patients with esophageal cancer with a pathologic complete response. Although there is no difference in the cumulative incidence of recurrence between esophageal adenocarcinoma and esophageal squamous cell carcinoma, patterns of recurrence appear to differ. Thus, treatment and surveillance strategies may be tailored appropriately.
OBJECTIVES: A pathologic complete response in patients with locally advanced esophageal cancer after chemoradiotherapy and surgery is associated with improved overall and disease-free survival. Nevertheless, approximately one third of patients with a pathologic complete response still have a recurrence. The aim of this study was to evaluate risk factors and patterns of recurrence in patients with locally advanced esophageal cancer who achieved a pathologic complete response after chemoradiotherapy and surgery. METHODS: We performed a retrospective review of a single-institution database of 233 patients with stage II and III esophageal cancer with a pathologic complete response after chemoradiotherapy and surgery between 1997 and 2017. A multivariable competing risk-regression model was used to identify predictors of recurrence. RESULTS: A total of 61 patients exhibited recurrence in this cohort, 43 with adenocarcinoma and 18 with squamous cell carcinoma. Five-year cumulative incidence of recurrence did not vary by histology. Univariable analysis revealed that poor tumor differentiation (hazard ratio, 2.28; P = .022) and advanced clinical stage (hazard ratio, 1.89; P = .042) are predictors of recurrence in the esophageal adenocarcinoma subgroup, whereas poor tumor differentiation remained the only independent predictor on multivariable analysis in the entire cohort (hazard ratio, 2.28; P = .009). Patients with esophageal adenocarcinoma had a higher incidence of distant recurrences, and patients with esophageal squamous cell carcinoma demonstrated a higher incidence of loco-regional recurrence (P = .039). CONCLUSIONS: Poor tumor differentiation is an independent risk factor for recurrence in patients with esophageal cancer with a pathologic complete response. Although there is no difference in the cumulative incidence of recurrence between esophageal adenocarcinoma and esophageal squamous cell carcinoma, patterns of recurrence appear to differ. Thus, treatment and surveillance strategies may be tailored appropriately.
Authors: D Vallböhmer; Arnulf H Hölscher; S DeMeester; T DeMeester; J Salo; J Peters; T Lerut; S G Swisher; W Schröder; E Bollschweiler; W Hofstetter Journal: Ann Surg Date: 2010-11 Impact factor: 12.969
Authors: Nabil P Rizk; Ennapadam Venkatraman; Manjit S Bains; Bernard Park; Raja Flores; Laura Tang; David H Ilson; Bruce D Minsky; Valerie W Rusch Journal: J Clin Oncol Date: 2007-02-10 Impact factor: 44.544
Authors: Robert A Meguid; Craig M Hooker; Joshua T Taylor; Laurence R Kleinberg; Stephen M Cattaneo; Marc S Sussman; Stephen C Yang; Richard F Heitmiller; Arlene A Forastiere; Malcolm V Brock Journal: J Thorac Cardiovasc Surg Date: 2009-12 Impact factor: 5.209
Authors: Nabil P Rizk; Venkatraman E Seshan; Manjit S Bains; David H Ilson; Bruce D Minsky; Laura Tang; Valerie W Rusch Journal: J Thorac Oncol Date: 2007-12 Impact factor: 15.609
Authors: Mariela Blum Murphy; Lianchum Xiao; Viren R Patel; Dipen M Maru; Arlene M Correa; Fatemeh G Amlashi; Zhongxing Liao; Ritsuko Komaki; Steven H Lin; Heath D Skinner; Ara Vaporciyan; Garrett L Walsh; Stephen G Swisher; Boris Sepesi; Jeffrey H Lee; Manoop S Bhutani; Brian Weston; Wayne L Hofstetter; Jaffer A Ajani Journal: Cancer Date: 2017-09-08 Impact factor: 6.860
Authors: P van Hagen; B P L Wijnhoven; P Nafteux; J Moons; K Haustermans; G De Hertogh; J J B van Lanschot; T Lerut Journal: Br J Surg Date: 2012-11-23 Impact factor: 6.939
Authors: R C Fields; V E Strong; M Gönen; K A Goodman; N P Rizk; D P Kelsen; D H Ilson; L H Tang; M F Brennan; D G Coit; M A Shah Journal: Br J Cancer Date: 2011-05-24 Impact factor: 7.640
Authors: Masaya Nakauchi; Elvira L Vos; Rebecca A Carr; Arianna Barbetta; Laura H Tang; Mithat Gonen; Ashley Russo; Yelena Y Janjigian; Sam S Yoon; Smita Sihag; Valerie W Rusch; Manjit S Bains; David R Jones; Daniel G Coit; Daniela Molena; Vivian E Strong Journal: Ann Surg Date: 2021-11-29 Impact factor: 13.787
Authors: Joerg Lindenmann; Melanie Fediuk; Nicole Fink-Neuboeck; Christian Porubsky; Martin Pichler; Luka Brcic; Udo Anegg; Marija Balic; Nadia Dandachi; Alfred Maier; Maria Smolle; Josef Smolle; Freyja Maria Smolle-Juettner Journal: Cancers (Basel) Date: 2020-07-27 Impact factor: 6.639
Authors: Smita Sihag; Tamar Nobel; Meier Hsu; Sergio De La Torre; Kay See Tan; Yelena Y Janjigian; Geoffrey Y Ku; Laura H Tang; Abraham J Wu; Steven B Maron; Manjit S Bains; David R Jones; Daniela Molena Journal: Ann Surg Date: 2020-11-17 Impact factor: 12.969